with the intact 131i-17-1a antibody , 21 out of 35 ( 60 % ) primary or secondary colorectal cancer sites were visualized , whereas all 21 nonepitheliomatous colic cancer sites or noncolic cancer sites were negative .
C0812305
17-1a
C0009402
colorectal cancer